AI Chat Search Browse Media On This Day Map Quotations Timeline Research Free Datasets Remembered About Contact

New HIV drug may lead to liver damage

Tue 10 Jun 2008 In: New Zealand Daily News View at Wayback

A new HIV drug of last resort currently prescribed in New Zealand is being watched closely amidst reports that it can cause liver damage, and may have contributed to two deaths overseas, when used in combination with commonly used existing HIV medications. Canadian and Australian HIV organisations have already flagged Darunavir (a.k.a. Prezista), currently supplied in NZ on a compassionate access scheme, as a possible contributing factor in drug-induced hepatitis and other serious liver problems when administered with ritonavir and other anti-retrovirals. It is being used to treat patients who have very few medication options left due to their infection being resistant to other drugs and drug combinations. Body Positive Auckland, NZ's largest advocacy and support organisation for people with HIV, says Darunavir is "a good drug," but may have unfortunate side-effects, a situation common with many of the medications people with HIV rely on. "We have referred the reports from Canada and Australia on to appropriate authorities," says Body Positive's Bruce Kilmister. "There are now concerns and we are watching this very closely." The NZ AIDS Foundation says anyone on the drug who is worried about liver problems to discuss the matter with their HIV specialist. "They should not discontinue any medication, but if they have concerns go to their HIV prescribing specialist and discuss the matter with them," says Eamonn Smythe, the NZAF's National Positive Health Manager. He says the Darunavir's manufacturers, Tibotec, are in contact with NZ clinicians over the concerns. 'Compassionate access' refers to a scheme allowed for under the Medicines Act whereby a new drug can be prescribed to those who have few or no other medication options, before it is approved for broader use and possible funding in New Zealand. It is not known how many HIV positive people are currently taking Darunavir in New Zealand as it is supplied directly by Tibotec and such data is generally regarded as commercially sensitive by drug companies.    

Credit: GayNZ.com Daily News staff

First published: Tuesday, 10th June 2008 - 10:13pm

Rights Information

This page displays a version of a GayNZ.com article that was automatically harvested before the website closed. All of the formatting and images have been removed and some text content may not have been fully captured correctly. The article is provided here for personal research and review and does not necessarily reflect the views or opinions of PrideNZ.com. If you have queries or concerns about this article please email us